<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338400</url>
  </required_header>
  <id_info>
    <org_study_id>FLA17028</org_study_id>
    <nct_id>NCT03338400</nct_id>
  </id_info>
  <brief_title>Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?</brief_title>
  <official_title>Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Reconstructive Surgery: Is There A Role?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To the investigators knowledge there are no studies in the literature evaluating the effect
      of Dexamethasone administration on patients undergoing outpatient vaginal prolapse surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The lifetime risk of undergoing surgical intervention for pelvic organ prolapse (POP) is
      estimated to be 10% and it is projected that from 2010 to 2050, the number of surgeries for
      POP will rise by 47.2%, from 166,000 to 245,970. In 1980, accounting for the rising costs of
      health care, congress approved Medicare to reimburse procedures performed at outpatient and
      ambulatory surgery centers. This led to an increasing number of stress incontinence (SUI)
      procedures being performed in the ambulatory setting from 34,968 in 1996 to 105,656 in 2006.
      However, the number of ambulatory POP surgeries decreased in the same time period. This was
      possibly due to the increase in the mean age of women undergoing ambulatory procedures for
      POP and SUI during that time periods.

      At the investigator's institution has performed outpatient surgeries for POP and SUI for the
      past 3 years. Patients have tolerated same day surgery with minimal complications. In the
      investigator's previous prospective study assessing satisfaction after outpatient surgeries
      for POP and SUI, patients had a decreased quality of recovery at 48 hours compared to
      baseline. The investigators also recognized that nausea and pain control could have been
      better addressed. Unpleasant postoperative nausea and vomiting, pain control, return to
      normal voiding and return of bowel function can influence the quality of recovery (QOR) from
      surgery.

      Postoperative nausea and vomiting (PONV) and pain management are particularly troubling for
      the patients. This might also delay discharge and prolong convalescence from the surgery.

      Several safe interventions have been assessed in the literature for alleviating PONV, pain
      and recovery from laparoscopic gynecologic surgery.

      Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced
      nausea and vomiting. The mechanism of action is not completely understood. It has been
      proposed that a single dose may hamper the production and release of anti-inflammatory
      mediators, thereby decreasing postoperative nausea, emesis, pain perception and Dexamethasone
      also has a central antiemetic effect by inhibition of prostaglandin and/or release of
      endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at
      induction is safe.

      Pauls et al in their recent study randomized patients undergoing vaginal prolapse surgery to
      receive Dexamethasone and noted a decrease in PONV and reduced requirement of a rescue
      antiemetic. Their model involved patients with overnight stay and the results may not be
      applicable to our population. They also noted that women who received Dexamethasone
      preoperatively were more likely to pass the voiding trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire: Quality of Recovery 40</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary aim is to evaluate whether standard administration of Dexamethasone at the time of anesthesia induction in patients undergoing vaginal reconstructive surgery would result in improved Quality of Recovery. The QoR-40 has 40 items that consider early postoperative health status of patients. These items cover five dimensions including emotional state (9 items), physical comfort (12 items), patient support (7 items), physical independence (5 items) and pain (7 items). All items are rated on a five-point Likert scale from one (worst) to five (best). All negative items were reversed to ease the interpretation. The total score (global score) was computed by summing all items. The minimum and maximum possible scores were 40 and 200, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea, Vomiting</measure>
    <time_frame>24 hrs</time_frame>
    <description>Patients will be administered a postoperative nausea, vomiting scale. The &quot;Post Operative Nausea Scale&quot; ranges from 0 to 77, where lower scores are improved outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Tract Infections</measure>
    <time_frame>until 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>6 weeks</time_frame>
    <description>Any patient that is re-admitted to the hospital and the reason for re-admission will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Level</measure>
    <time_frame>24 hours</time_frame>
    <description>numerical pain scale ranges from 0 to 10, where lower scores represent less pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Quality of Recovery</condition>
  <condition>Same Day Surgery</condition>
  <condition>Nausea and Vomiting, Postoperative</condition>
  <condition>Vaginal Prolapse</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the Dexamethasone arm will be administered the drug at the time of induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm patients will receive normal saline at the time of induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women over the age of 18

          2. Women scheduled for vaginal POP reconstructive surgery with or without concomitant
             anti-incontinence procedure and with or without hysterectomy

          3. ASA class 1-2

        Exclusion Criteria:

          1. Daily use of steroids, antiemetics in the month prior to surgery

          2. Chronic pain requiring daily opioid treatment

          3. History of allergy/intolerance to Dexamethasone

          4. ASA class 3

          5. Numerical Pain score of more than 4 at baseline

          6. Renal/Liver disease

          7. Diabetes mellitus

          8. Pregnancy

          9. Inability to answer questionnaires

         10. Any systemic infections

         11. Immuno compromised status

         12. Patients with planned overnight stay
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The surgeries that are performed are only vaginal prolapse surgeries in a female pelvic medicine and reconstructive surgery department.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Willy Davila</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Head</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <results_first_submitted>August 21, 2018</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Recovery, Dexamethasone, Same day surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03338400/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>Patients in the Dexamethasone arm will be administered the drug at the time of induction.
Dexamethasone: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>The placebo arm patients will receive normal saline at the time of induction.
Normal saline: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>Patients in the Dexamethasone arm will be administered the drug at the time of induction.
Dexamethasone: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>The placebo arm patients will receive normal saline at the time of induction.
Normal saline: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="40" upper_limit="83"/>
                    <measurement group_id="B2" value="65" lower_limit="34" upper_limit="85"/>
                    <measurement group_id="B3" value="65" lower_limit="34" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="B2" value="28" lower_limit="21" upper_limit="39"/>
                    <measurement group_id="B3" value="27" lower_limit="18" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Questionnaire: Quality of Recovery 40</title>
        <description>The primary aim is to evaluate whether standard administration of Dexamethasone at the time of anesthesia induction in patients undergoing vaginal reconstructive surgery would result in improved Quality of Recovery. The QoR-40 has 40 items that consider early postoperative health status of patients. These items cover five dimensions including emotional state (9 items), physical comfort (12 items), patient support (7 items), physical independence (5 items) and pain (7 items). All items are rated on a five-point Likert scale from one (worst) to five (best). All negative items were reversed to ease the interpretation. The total score (global score) was computed by summing all items. The minimum and maximum possible scores were 40 and 200, respectively.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Patients in the Dexamethasone arm will be administered the drug at the time of induction.
Dexamethasone: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>The placebo arm patients will receive normal saline at the time of induction.
Normal saline: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.</description>
          </group>
        </group_list>
        <measure>
          <title>Questionnaire: Quality of Recovery 40</title>
          <description>The primary aim is to evaluate whether standard administration of Dexamethasone at the time of anesthesia induction in patients undergoing vaginal reconstructive surgery would result in improved Quality of Recovery. The QoR-40 has 40 items that consider early postoperative health status of patients. These items cover five dimensions including emotional state (9 items), physical comfort (12 items), patient support (7 items), physical independence (5 items) and pain (7 items). All items are rated on a five-point Likert scale from one (worst) to five (best). All negative items were reversed to ease the interpretation. The total score (global score) was computed by summing all items. The minimum and maximum possible scores were 40 and 200, respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="14.49"/>
                    <measurement group_id="O2" value="167" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea, Vomiting</title>
        <description>Patients will be administered a postoperative nausea, vomiting scale. The &quot;Post Operative Nausea Scale&quot; ranges from 0 to 77, where lower scores are improved outcomes.</description>
        <time_frame>24 hrs</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Tract Infections</title>
        <time_frame>until 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmissions</title>
        <description>Any patient that is re-admitted to the hospital and the reason for re-admission will be collected.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Level</title>
        <description>numerical pain scale ranges from 0 to 10, where lower scores represent less pain.</description>
        <time_frame>24 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over 6 month period of time.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>Patients in the Dexamethasone arm will be administered the drug at the time of induction.
Dexamethasone: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>The placebo arm patients will receive normal saline at the time of induction.
Normal saline: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Ossin</name_or_title>
      <organization>Cleveland Clinic Florida</organization>
      <phone>954-659-5559</phone>
      <email>ossind@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

